bgb324

Myelodysplastic Syndromes

BerGenBio ASAPhase 2Active

CCC

54/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 47/ 100
Competitive Position: 65/ 100

Competitive context

314 Active assets in the Myelodysplastic Syndromes cohort.

Asset / Sponsor	Phase	Rating
Fludarabine Sawa Ito, MD	Phase 4	BB
Cyclophosphamide Sawa Ito, MD	Phase 4	BB
Cytosin-Arabinosid The First Affiliated Hospital of Soochow University	Phase 4	BB
FILGRASTIM City of Hope Medical Center	Phase 4	BB
Daunorubicin OHSU Knight Cancer Institute	Phase 3	BB

View all 50 →

Same molecule, other indications

bgb324 is also rated in:

non-small cell lung carcinomaDormant

CCC

Indicative ·

52 / 100

acute myeloid leukemiaDormant

CCC

Indicative ·

52 / 100

lung cancerDormant

CCC

Indicative ·

51 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.